This inventor holds 3 USPTO granted patents and 9 published patent applications. Top assignees: Wisconsin Alumni Research Foundation, Dana-Farber-Cancer Institute Inc., University of California. Active years: 2017-2026.
Company Filing History:
2 out of 4,226 
1 out of 1,264 
1 out of 15,964 
Years Active: 2017-2026
Title: Innovations of Nir London
Introduction
Nir London is a notable inventor based in Rehovot, Israel. He has made significant contributions to the field of microbial growth inhibition and pathogenic microorganism virulence attenuation. With a total of 3 patents, his work focuses on innovative compounds that target specific microbial processes.
Latest Patents
Nir London's latest patents include inhibitors of UDP-galactopyranose mutase. These compounds and their salts are designed to inhibit microbial growth or reduce the virulence of pathogenic microorganisms. The inventions feature triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles. The methods outlined in these patents aim to inhibit the growth of various microbial pathogens, including mycobacterium, as well as eukaryotic human and animal pathogens, fungi, and nematodes.
Career Highlights
Throughout his career, Nir London has worked with esteemed organizations such as the Wisconsin Alumni Research Foundation and the University of California. His research has contributed to advancements in the understanding and treatment of infections caused by both prokaryotic and eukaryotic pathogens.
Collaborations
Nir London has collaborated with notable colleagues, including Laura Lee Kiessling and Virginia E Kincaid. These partnerships have further enriched his research and innovation in the field.
Conclusion
Nir London is a prominent inventor whose work in microbial inhibition has the potential to impact the treatment of various infections. His innovative patents reflect a commitment to advancing scientific knowledge and improving public health.